| 589.25 1.1 (0.19%) | 12-06 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 731.01 | 1-year : | 853.82 |
| Resists | First : | 625.86 | Second : | 731.01 |
| Pivot price | 591.23  |
|||
| Supports | First : | 579.76 |
Second : | 551.26 |
| MAs | MA(5) : | 587.63 |
MA(20) : | 595.01 |
| MA(100) : | 554.43 |
MA(250) : | 450.73 |
|
| MACD | MACD : | 1.1 |
Signal : | 2.8 |
| %K %D | K(14,3) : | 32.4 |
D(3) : | 26.9 |
| RSI | RSI(14): 50.2 |
|||
| 52-week | High : | 629.96 | Low : | 309.2 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ LLY ] has closed above bottom band by 38.2%. Bollinger Bands are 76.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 7 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 594.79 - 597.19 | 597.19 - 599.66 |
| Low: | 578.5 - 580.99 | 580.99 - 583.56 |
| Close: | 585.17 - 589.49 | 589.49 - 593.95 |
Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes. The company provides Alimta for non-small cell lung cancer (NSCLC) and malignant pleural mesothelioma; Cyramza for metastatic gastric cancer, gastro-esophageal junction adenocarcinoma, metastatic NSCLC, metastatic colorectal cancer, and hepatocellular carcinoma; Erbitux for colorectal cancers, and various head and neck cancers; Retevmo for metastatic NSCLC, medullary thyroid cancer, and thyroid cancer; Tyvyt for relapsed or refractory classic Hodgkin's lymph and non-squamous NSCLC; and Verzenio for HR+, HER2- metastatic breast cancer, node positive, and early breast cancer. It offers Olumiant for rheumatoid arthritis; and Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis. The company offers Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Emgality for migraine prevention and episodic cluster headache; and Zyprexa for schizophrenia, bipolar I disorder, and bipolar maintenance. Its Bamlanivimab and etesevimab, and Bebtelovimab for COVID-19; Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. The company has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; AbCellera Biologics Inc.; Junshi Biosciences; Regor Therapeutics Group; Lycia Therapeutics, Inc.; Kumquat Biosciences Inc.; Entos Pharmaceuticals Inc.; and Foghorn Therapeutics Inc. Eli Lilly and Company was founded in 1876 and is headquartered in Indianapolis, Indiana.
Wed, 06 Dec 2023
Eli Lilly & Co. stock outperforms market on strong trading day - MarketWatch
Tue, 05 Dec 2023
Eli Lilly vs. Novo Nordisk: The pros deliver their verdict on the viral weight-loss stocks - CNBC
Tue, 05 Dec 2023
Eli Lilly and Company’s GLP-1 Weight Loss Drug Is Now Available in the US for as Low as $25 - Wccftech
Tue, 05 Dec 2023
Eli Lilly announces U.S. availability of weight loss drug Zepbound (NYSE:LLY) - Seeking Alpha
Tue, 05 Dec 2023
Eli Lilly (NYSE:LLY) Has A Pretty Healthy Balance Sheet - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Outperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Drug Manufacturers—General
|
|
| Shares Out | 949 (M) |
| Shares Float | 898 (M) |
| Held by Insiders | 0.1 (%) |
| Held by Institutions | 83.9 (%) |
| Shares Short | 5,840 (K) |
| Shares Short P.Month | 6,390 (K) |
| EPS | 5.55 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 12.47 |
| Profit Margin | 15.5 % |
| Operating Margin | 37.2 % |
| Return on Assets (ttm) | 11.6 % |
| Return on Equity (ttm) | 46.4 % |
| Qtrly Rev. Growth | 36.7 % |
| Gross Profit (p.s.) | 23.07 |
| Sales Per Share | 33.78 |
| EBITDA (p.s.) | 11.92 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | 5,710 (M) |
| Levered Free Cash Flow | 3,900 (M) |
| PE Ratio | 106.17 |
| PEG Ratio | 4 |
| Price to Book value | 47.21 |
| Price to Sales | 17.44 |
| Price to Cash Flow | 97.96 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|